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ABSTRACT
Somatic variant analysis of a tumour sample and
its matched normal has been widely used in can-
cer research to distinguish germline polymorphisms
from somatic mutations. However, due to the exten-
sive intratumour heterogeneity of cancer, sequenc-
ing data from a single tumour sample may greatly
underestimate the overall mutational landscape. In
recent studies, multiple spatially or temporally sep-
arated tumour samples from the same patient were
sequenced to identify the regional distribution of so-
matic mutations and study intratumour heterogene-
ity. There are a number of tools to perform somatic
variant calling from matched tumour-normal next-
generation sequencing (NGS) data; however none of
these allow joint analysis of multiple same-patient
samples. We discuss the benefits and challenges
of multisample somatic variant calling and present
multiSNV, a software package for calling single nu-
cleotide variants (SNVs) using NGS data from mul-
tiple same-patient samples. Instead of performing
multiple pairwise analyses of a single tumour sample
and a matched normal, multiSNV jointly considers all
available samples under a Bayesian framework to in-
crease sensitivity of calling shared SNVs. By leverag-
ing information from all available samples, multiSNV
is able to detect rare mutations with variant allele fre-
quencies down to 3% from whole-exome sequencing
experiments.
INTRODUCTION
Somatic single nucleotide variants (SNVs) are point muta-
tions found in the genomes of tumour cells, but not their
matched normals. They often play important roles in tu-
mour initiation, progression andmetastasis by changing the
amino acid sequence (missense mutation) or prematurely
truncating encoded proteins (nonsense mutation). Discov-
ering such cancer-related SNVs is confounded by the pres-
ence ofmillions of germline pointmutations. To distinguish
somatic from germline SNVs, it has become routine to se-
quence matched tumour-normal samples from the same in-
dividual.
Many cancer types are known to have a high degree of
intratumour heterogeneity, so that the mutations present in
a single tumour sample might not represent the full set of
mutations in a particular cancer patient. As a result, multi-
region sequencing studies, where multiple samples from the
same individual are sequenced, are becoming increasingly
popular.
Shah et al. (2009) assessed the mutational spectrum in
a patient with metastatic lobular breast cancer and iden-
tified that out of 32 coding mutations, 19 were specific to
metastases (1). Similarly, Yachida et al. (2010) compared
somatic mutations in seven patients with metastatic pan-
creatic cancer and inferred that a mean of 36% of muta-
tions were ‘progressor’ mutations not detectable across all
samples of the same patient (2). Gerlinger et al. (2012) per-
formed whole-exome sequencing on multiple samples from
patients with metastatic clear cell renal carcinoma and in-
ferred a branched model of tumour evolution with approxi-
mately 31% to 37% of somatic mutations common to all tu-
mour samples (3). Similarly, Zhang et al. (2014) performed
whole-exome sequencing on 48 tumour regions from 11 lo-
calized lung adenocarcinomas and found that 76% of all
mutations were common to all regions of the same patient
(4). De Bruin et al. (2014) sequenced 25 regions from seven
nonsmall cell lung cancer patients and assessed how the
poor prognosis of this cancer type might be linked to in-
tratumour heterogeneity and divergent genomic instability
processes (5).
Analysis ofmultiregion sequencing poses a new challenge
for somatic variant calling, as both somatic sites and the dis-
tribution of somatic mutations across related samples need
to be identified. Accurate and sensitive detection of the re-
gional distribution of mutations can be key to reconstruct-
ing the evolution of a tumour, so somatic variant callers
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need to have enough power to identify rare mutations, with-
out overcalling events.
Calling SNVs from related samples
Somatic SNV calling has rapidly evolved over the past 5
years or so, from simple approaches based on hard thresh-
olding on the number of variant reads, to fully probabilistic
models. These probabilistic approaches report confidence
scores by directly modelling the uncertainty in the sequenc-
ing data. This uncertainty is the result of Polymerase chain
reaction (PCR) errors, contamination from normal cells, se-
quencing artefacts and mapping errors as well as the lim-
ited depth of coverage. The premise of sophisticated somatic
variant callers is to allowoptimal prediction of somatic vari-
ation at low depth of coverage and low variant allele fre-
quencies.
Some of the first probabilistic SNV callers such as (6)
called mutations in tumour and matched normal samples
separately and identified somatic SNVs post-hoc by exclud-
ing mutations found in both the tumour and its matched
normal. These were succeeded by their Bayesian equiva-
lents, which jointly inferred mutations in tumour-normal
pairs via a probabilistic model that accounted for the corre-
lation between two samples from the same patient (7).
Even though there are now several excellent pairwise so-
matic variant callers, none of them can jointly analysemulti-
ple related tumour samples. These are therefore analysed ei-
ther independently using one tumour-normal pair at a time
(5), or by using GATK’s UnifiedGenotyper (8). The former
method is inconvenient as it results in making multiple re-
dundant analyses of the normal sample and requires merg-
ing different output files. The latter approach is not ideal
as GATK’s UnifiedGenotyper is specifically tuned to detect
germline rather than somatic mutations from multiple un-
related samples (9,10). Most importantly, none of the ap-
proaches can easily be adapted to account for known pat-
terns of relatedness between samples from the same patient.
We argue that fully Bayesian approaches can improve so-
matic variant calling frommultiple related samples, in a sim-
ilar manner that these approaches have improved somatic
variant calling from matched tumour-normal pairs com-
pared to independent sample analysis. In this contribution,
we discuss the advantages and challenges of extending the
current Bayesian paradigm to multiple same-patient sam-
ples. As a proof of principle, we present multiSNV, a first
version of a somatic variant caller that extends pairwise
analysis of tumour-normal pairs to joint analysis of mul-
tiple samples from the same patient.
multiSNV calls somatic SNVs across all available same-
patient samples without pooling reads. It is based on a
Bayesian framework that captures the relatedness between
samples by modelling the probability of a mutation in a
given sample, conditioned on the somatic status of all other
samples. We present the statistical model, benchmark it on
simulated and real data and compare performance to alter-
native workflows. We find that when multiple tumour sam-
ples are available, multisample variant calling can identify
validated mutations with higher sensitivity.
MATERIALS AND METHODS
Modelling a multisample variant caller
Most current (pairwise) somatic variant callers are based on
some approximation of the joint distribution of the tumour
and normal genotypes, P(GN,GT), derived by directly mod-
elling the dependency between the tumour and normal sam-
ple, P(GT|GN). A Bayesian approach to multisample vari-
ant calling should similarly try to infer the joint distribu-
tion of genotypes over n tumour samples and the normal,
P(GN,GT1 , . . . ,GTn ). Since tumour samples often consist
of cells with different genotypes and unknown copy num-
ber, we argue that modelling the joint distribution of allelic
compositions is more appropriate. The allelic composition
of a patient sample denotes the aggregate set of alleles de-
tected at a genomic locus, so when the allelic composition
in a tumour sample, STi , does not match the allelic compo-
sition in the normal, SN, the site may be treated as an SNV
candidate.
Statistical model used in multiSNV
In this first version of a multisample somatic variant
caller, we infer the most likely set of allelic compositions
{SN, ST1 , . . . , STn } by using Gibbs sampling to approximate
the posterior distribution P(SN, ST1 , . . . , STn |D).D denotes
the sequencing data (read bases with their correspond-
ing base qualities) from the normal sample and n tumour
samples so that at a particular chromosomal locus, D =
{DN,DT1 , . . . ,DTn }.
To implement Gibbs sampling, we initialize the allelic
compositions to random values and then draw a value for
the allelic composition of each sample from its correspond-
ing conditional distribution. Each newly drawn allelic com-
position value is used to update the conditional distribu-
tions of the rest of the samples and this procedure is re-
peated for a large number of iterations to allow the Markov
chain to converge. Upon convergence, samples drawn from
the conditionals may be assumed to come from the required
joint distribution. We then infer as a point estimate of each
allelic composition S, the most frequently drawn state.
A list of parameters used to describe the inference model
in multiSNV is given in Table 1.
Modelling the conditional distributions. The conditional
probability distribution of the allelic composition in the
normal sample SN is given by the product of the likelihood
of the sequenced reads at a locus and the prior probability
of observing SN given the allelic composition in the tumour
samples:
P(SN|ST1 , . . . , STn ,D) ∝ P(D|SN, ST1 , . . . , STn )P(SN|ST1 , . . . , STn )
We assume conditional independence of the form:
P(D|SN, ST1 , . . . , STn ) = P(DN,DT1 , . . . ,DTn |SN, ST1 , . . . , STn )
= P(DN |SN, ST1 , . . . , STn )
n∏
i=1
P(DTi |SN, ST1 , . . . , STn )
We also assume that the likelihood of the sequencing data in
patient sample k depends only on the inferred sample allelic
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Table 1. List of parameters used to describe the inference model in multiSNV
Parameter Description Comments
n Number of tumour samples User-specified
SN Allelic composition in normal sample Estimated (one to two alleles allowed)
STi Allelic composition in tumour sample i Estimated (one to three alleles allowed)
k Denotes sample k k ∈ {N, T1. . .Tn}
Mk Number of alleles in allelic composition Sk Computed from inferred Sk
D Pileup of bases and corresponding base qualities in all
samples
Read from pileup file
DN Pileup of bases and corresponding base qualities in
normal sample
Read from pileup file
DTi Pileup of bases and corresponding base qualities in
tumour sample i
Read from pileup file
rkj Allele supported by read j in sample k Read from pileup file
ekj Error probability of read j in sample k Read from pileup file
vkτ Total number of reads in sample k that support allele  Read from pileup file
f k The probability distribution of alleles in sample k Estimated by maximizing F(g|Dk, Sk, ak)
ak Vector of shape parameters of Dirichlet prior on f k Uniform prior
 Mutation rate User-specified (default is 3 × 10−7)
N The set of values of SN with nonzero prior probability All monoallelic and diallelic compositions (total of 10)
z Sampling probability of allelic composition z Integrated out
z Parameters of Dirichlet prior on z of STi As described in Materials and Methods
δNz Parameters of Dirichlet prior on z of S
N As described in Materials and Methods
cTiz Number of tumour samples excluding Ti with allelic
composition z
From most recent draw of the Gibbs sampler
nz Number of tumour samples with allelic composition z From most recent draw of the Gibbs sampler
w Scales pseudocounts for Dirichlet prior of allelic
compositions
10 × (n + 1)
multiSNV analyses each location in the genome independently, so these parameters refer to a single genomic locus.
composition, so that:
P(Dk|SN, ST1 , . . . , STn ) = P(Dk|Sk)
It follows that the conditional probability distribution of the
allelic composition in the normal sample is given by:
P(SN|ST1 , . . . , STn ,D) ∝ P(DN|SN)P(SN|ST1 , . . . , STn )
Similarly, the conditional probability distribution of the al-
lelic composition in tumour sample i is given by:
P(STi |S−Ti , SN,D) ∝ P(DTi |STi )P(STi |SN, S−Ti )
where S−Ti denotes the set of all tumour allelic compositions
except STi . The following subsections describe our choice of
likelihood and priors.
Likelihood model. The pileup of aligned reads that cover a
particular chromosomal location in patient sample k is rep-
resented by vector rk, where each element rkj of the vector
is ∈ {A, C, G, T}. Each base has an associated base quality
that gives the overall probability that the base has been mis-
called. In our model, we assume that all three base calling
errors are equally probable, so that if for example, rkj = A,
the overall probability that the base has been miscalled as
A is ekj , and the probability that the base has been miscalled
as A given that it is C, G or T, is uniform. It is convenient
to define
Gk =
{
(gA, gC, gG, gT) : gi ≥ 0, gA + gC + gG + gT = 1,
gi = 0 if i /∈ Sk
}
The probability distribution of alleles in sample k is denoted
by f k ∈ Gk. The probability of base rkj being called as  ∈ {A,
C, G, T} is
P(rkj = τ |Sk, f k) = (1 − ekj ) f kτ +
ekj
3
(1 − f kτ )
Since the bases rkj are independent, the likelihood of the se-
quencing data Dk is given by the product of the individual
likelihoods:
P(Dk|Sk, f k) =
∏
j
P(rkj |Sk, f k)
Estimating f k. To estimate the probabilities f kwe compute
the maximum-a-posteriori estimate from the posterior den-
sity F(g|Dk, Sk, ak), g ∈ Gk, assuming a flat Dirichlet prior
on the nonzero elements of Gk, parameterized by ak.
For the normal sample, nonzero akτ are set to about five
times themedian normal coverage as wewant to bias our ra-
tio towards allele fractions of 1 for homozygous sites and 0.5
for heterozygous sites. For tumour samples, we use a weaker
prior with all nonzero akτ set to around 20% of the median
coverage in tumour samples.
We compute the likelihood P(Dk|Sk, g) in the limit ekj →
0, expecting this to be a good approximation as low quality
bases are filtered out. Under these assumptions, the poste-
rior F(g|Dk, Sk, ak) is Dirichlet, parameterized by akτ + vkτ
where vkτ is the total number of reads in sample k that sup-
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port allele  . This gives:
f kτ =
⎧⎪⎨
⎪⎩
vkτ + akτ − 1∑
τ∈Sk
(vkτ + akτ ) − Mk
, τ ∈ Sk
0, τ /∈ Sk
whereMk is the number of alleles in the allelic composition
Sk.
The explicit modelling of the probability distribution of
alleles  ∈ {A, C, G, T} allows us to represent tumour sam-
ples as a heterogeneous mixture of cells with potential copy
number aberrations. This improves sensitivity of detecting
rare variants or variants at sites with altered ploidy.
Modelling the prior probability of each tumour allelic compo-
sition. We approximate the distribution of tumour allelic
compositions {ST1 , . . . , STn } as amultinomial sample from a
universe with k= 24 − 2 types (all allelic compositions with
one to three alleles), and sampling probabilities 1, . . . , k.
The z have a Dirichlet prior parameterized by z, defined
according to how close a tumour allelic composition z is to
the inferred normal allelic composition SN. We set the pa-
rameter z to w, whenever the allelic composition z is one
mutation away from SN, or in other words when z has one
extra nucleotide compared to SN. Since this corresponds to
a somatic SNV at the locus, the default value of  is set to
3 × 10−7, which is close to the estimated somatic mutation
rate. The parameter w is a weighting factor. For all other
allelic compositions (excluding z = SN), we set z to w2,
as we consider these transitions to be less likely. We set z
for z = SN so that∑
z
δz = w. The prior probability of each
tumour allelic composition is:
P(STi = z|S−Ti , SN) = c
Ti
z + δz∑
z
(cTiz + δz)
where cTiz is the number of times allelic composition z has
been observed in the set of tumour allelic compositions ex-
cluding STi . As cTiz increases, P(S
Ti = z|S−Ti , SN) also in-
creases, so that the algorithm has more power to detect
shared mutations. To avoid overcalling these shared events,
the weighting factor, w, is set to 10 × (n + 1), where n is the
number of tumour samples.
Modelling the prior probability of the normal allelic com-
position. We use a similar approach to model the prior
probability of SN, assuming the normal sample is pure and
diploid. We denote the set of allelic compositions with one
or two alleles by N and let:
P(SN = z|ST1 , . . . , STn ) =
{
0, z /∈ N
nz+δNz∑
z∈N
(nz+δNz ) , z ∈ N
where nz is the number of tumour samples with allelic com-
position equal to z, and δNz is the parameter of the Dirichlet
prior on the sampling probability z, where z ∈ N . These
parameters are defined according to how close an allelic
composition z is to the reference allele:
δNz =
⎧⎪⎨
⎪⎩
wα, heterozygous reference
wβ, heterozygous variant
wγ, homozygous variant
wδ, homozygous reference
with values defined as suggested in (11), following (12), so
that α = 3.34 × 10−4, β = 8.33 × 10−8, γ = 1.665 × 10−4,
δ = 0.9985. The weighting factor w is similarly set to 10 ×
(n + 1).
Software package
The multiSNV software package has been implemented in
C++ and is available at http://www.compbio.group.cam.ac.
uk/software/multisnv
RESULTS
Benchmarking multiSNV
We evaluated multiSNV using both simulated datasets
and real exome-sequencing data from a validated multi-
region sequencing study on clear-cell renal carcinoma (3).
We benchmarked the performance of multiSNV against
four other variant callers: SomaticSniper, MuTect, Uni-
fiedGenotyper and Platypus as these represent well the
currently available options for analysing multiple related
samples. SomaticSniper (13) and MuTect (14) call somatic
SNVs from tumour-normal pairs, so analysis of multiple
tumour samples requires calling variants on each tumour-
normal pair independently and then combining calls. In
contrast, both Platypus (15) and UnifiedGenotyper (9,10)
can call variants from multiple samples, but neither has
been designed to address the challenges of calling somatic
variants from matched tumour/normal samples.
Simulation study
We simulated reads from fourmatched tumour samples and
a normal, under a model of uniform sequencing depth with
perfectly aligned reads and independent sequencing error,
using SimulateReadsForVariants from GATK. The proba-
bility of sampling a variant allele was set to the variant al-
lele frequency, and sequencing noise was added at the base
quality rate. We ran multiSNV and the four other variant
callers using settings close to default|-details may be found
in the Supplementary Material.
Improved sensitivity of calling shared somatic events. We
simulated reads for the simple case where SNVs are found
in all tumour samples at the same frequency. We computed
the sensitivity of each variant caller, given by the ratio of
true positive calls to the total number of simulated SNVs
(3000). Reads were simulated with base quality score of Q30
and the simulation experiment was repeated for variant al-
lele frequencies between 0.1 and 0.5 and sequencing depths
between 15 × and 60 ×. We ran multiSNV and compared
its sensitivity to the two other multisample callers (Platy-
pus and UnifiedGenotyper) and the two pairwise somatic
variant callers (SomaticSniper and MuTect). As shown in
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Figure 1. (a) Sensitivity in detecting shared mutations of increasing variant allele frequency at three different sequencing depths, using simulated reads of
base quality score Q30. (b) Observed false-positive rate per megabase as a function of sequencing depth in the presence of 0 and 5% tumour contamination
in the normal. Reads were simulated under a model of independent and uniform sequencing error, introduced at base quality rates of Q15, Q20 and Q30.
Figure 1, the three multisample callers outperform Somat-
icSniper and MuTect, and multiSNV is consistently more
sensitive than all other methods. This is particularly evident
at low allele frequencies. For example, at a variant allele fre-
quency of 0.1 and sequencing depth 60, multiSNV outper-
forms the second most sensitive variant caller by more than
70%. This suggests that even though joint analysis of multi-
ple samples enhances sensitivity compared to independent
pairwise analyses, there are clear advantages to a multisam-
ple caller that is tailored to detect somatic variation from
related tumour samples.
Robustness to independent sequencing noise. To confirm
that the enhanced sensitivity of multiSNV is not at the
expense of a high false-positive rate, we assessed the ro-
bustness of multiSNV to independent sequencing noise at
default settings. This was done by simulating reads with
Phred-scaled base qualities of 15, 20 and 30, and setting
the variant allele frequency to 0, for different sequencing
depths. We computed the false-positive rate, defined as the
ratio of the number of false-positive calls to the total num-
ber of simulations (100 000).
False-positive rate results for all five variant callers for
sequencing depths between 10 and 60 are shown in Figure 1.
Most variant callers handle this type of sequencing error
well, but multiSNV is one of the better performing with a
false-positive rate lower than 10 per megabase, even at very
low base qualities (Q15) and low sequencing depth (10). It
drops towards 0 as noise levels decrease or sequencing depth
increases.
Robustness to contamination of the normal by tumour cells.
We also tested robustness to false positives when the normal
sample is contaminated by tumour cells, by setting the vari-
ant allele frequency in all tumour samples to 0.5 and intro-
ducing 5% contamination in the normal sample. The results
of this simulation experiment are summarized in Figure 1.
multiSNV has some inherent robustness to contamination
of the normal (we bias the normal to be homozygous ref-
erence and the expected allele fractions in the normal to be
close to 0.5 or 1); however, the likelihood model itself does
not explicitly account for any possible contamination from
tumour cells. This implies that all variant reads in the nor-
mal are attributed to random sequencing error. It follows
that the false-positive rate is higher when simulated reads
have higher base qualities, as the probability of observing
these high-quality variant reads is very low if the normal is
homozygous reference, leading to more false-positive calls.
We note that if there is significant contamination in the nor-
mal, the likelihood model should be extended accordingly.
Clear-cell renal carcinoma data
Simulations fail to capture the noise and complexity of real
datasets, so we also evaluated performance of multiSNV us-
ing the two datasets from (3) where exomes from multiple
tumour samples of two patients with metastatic clear cell
carcinoma were sequenced. In patient 1, we had access to
whole-exome sequencing data from 11 spatially separated
samples, of which three came from distant metastases, seven
came from the primary tumour collected after nephrectomy
and one came from germline DNA. In patient 2, we used
whole-exome sequencing data from eight tumour samples
of which two came from metastases, five came from the pri-
mary tumour and one came from germline DNA.
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Originally, SNVMix2 had been used to call somatic vari-
ants and the regional distribution of a subset of nonsynony-
mous, coding SNVs was verified using Sanger sequencing.
We ran multiSNV, SomaticSniper, MuTect, UnifiedGeno-
typer and Platypus and compared their overall number
of calls, concordance with dbSNP and sensitivity in cor-
rectly detecting the regional distribution of the validated
SNVs. We did not compare performance to SNVMix2 as
this method analyses samples independently instead of as
tumour-normal pairs.
Somatic variant analysis. We ran all tools using the set-
tings described in the Supplementary Material (default un-
less otherwise stated). Only sites with nonzero depth in
all samples were considered in the analysis. Approximately
2.7% of somatic events called by multiSNV involved a
germline heterozygous site, of which 65% were loss-of-
heterozygosity events.We excluded these sites from the com-
parative analysis because MuTect rejects sites where the
normal appears to be contaminated or heterozygous, and
SomaticSniper, Platypus and UnifiedGenotyper do not call
SNVs on germline heterozygous sites. Overall, less than
0.9% of somatic events failed to reach convergence when
multiSNV was allowed to run up to a maximum of 3000
Gibbs cycles. This was generally due to extremely low vari-
ant allele frequencies, and/or low depth. A summary of
variant analysis results from multiSNV and the other vari-
ant callers is shown in Table 2.
Platypus called the fewest somatic sites (2530) when no
filtering was applied, followed byUnifiedGenotyper (6294).
To get a high confidence dataset fromPlatypus, we kept only
sites that were flagged as ‘alleleBiased’ and ‘PASS’, which
reduced the number of sites by more than three times. Sim-
ilarly, when we used the publicly available scripts suggested
for filtering SomaticSniper (Supplementary Material), the
raw number of somatic sites dropped bymore than 17 times,
down to 622.
We applied simple filters to the output of multiSNV, as
described in the Supplementary Material. This reduced the
number of somatic sites called from 21 504 to 7736.MuTect
found the most somatic sites (274 792); however, only 1410
satisfied the six built-in filters and were included in its high
confidence (HC) calls.
Overlap with dbSNP. A frequent source of false positives
in somatic variant analysis is germline variation being mis-
called as somatic. We compared the overlap of somatic calls
made by each variant caller with dbSNP build 137 (exclud-
ing sites after build 129). It is likely that not all sites called
as somatic and found in dbSNP are false positives; how-
ever, on average this is a good measure of the false-positive
rate. multiSNV had the lowest overlap with dbSNP on both
unfiltered (6.93%) and high confidence (6.15%) mode, fol-
lowed by SomaticSniper (8.82%).
Sensitivity in calling validated somatic sites and SNVs. We
used the set of validated mutations to compare how many
of the validated somatic sites and SNVs were called by each
method. Overall, 27 SNV sites from patient 1 and 17 SNV
sites from patient 2 were originally validated. multiSNV (in
both modes) and UnifiedGenotyper called all SNV sites,
whereas SomaticSniper missed three, even when no filters
were applied. MuTect and Platypus in the unfiltered mode
called all sites, but in both cases two were then rejected by
the built-in filters.
SNVs were validated in several patient samples at these
somatic sites, as reported in the Supplementary Material of
(3). Out of 432 candidate SNVs, 171 were found to be gen-
uine somatic variants. We compared the ‘validated sensitiv-
ity’ of the five methods by computing the number of vali-
dated SNVs called divided by the total number of validated
SNVs.
Figure 2 shows all true-positive and false-negative SNVs
plotted as a function of sequencing depth and variant al-
lele frequency, from reads filtered at mapping quality Q30
and base quality Q20. Out of 171 validated SNVs, multi-
SNV had five false negatives of which four were present
at observed allele frequencies of 0, indicating that these
sites could only be identified by subsequent validation ex-
periments. Compared to MuTect (HC) and SomaticSniper
(HC), UnifiedGenotyper, Platypus andmultiSNV canmore
readily call SNVs at low sequencing depth as they consider
multiple samples jointly, which improves power. The ma-
jority of false negatives with UnifiedGenotyper and Platy-
pus were the result of very low variant allele frequencies,
which appeared even at relatively high sequencing depth.
This is because these tools are not somatic variant callers
as such, so they lack the sensitivity to rare variants of tools
like MuTect. SomaticSniper had the most false negatives
and these appeared both at low sequencing depth and low
variant allele frequency. In general, the performance of So-
maticSniper is compromised compared to MuTect because
it assumes that variant allele frequencies are close to 0.5.
As seen from Figure 2, multiSNV outperformed all other
tools in terms of having the least number of false negatives,
and was the only method whose validated sensitivity did
not decrease after applying filters. By leveraging informa-
tion from multiple samples, multiSNV was able to detect
somatic mutations appearing at allele frequencies of 2.8%
compared to 4.4% for MuTect, 5.9% for Platypus, 7.7% for
UnifiedGenotyper and 12.0% for SomaticSniper.
A consensus approach. Platypus is unique in the cohort of
variant callers considered, as it uses local de novo assem-
bly, local realignment and probabilistic haplotype estima-
tion, and it jointly calls indels, complex polymorphisms and
SNPs (15). Unlike other variant callers, it has been shown
to achieve high specificity without the need for extensive
false-positive filtering. Compared to multiSNV, Platypus
achieved a lower validated sensitivity (90.1 versus 97.1%),
while calling 10 × fewer somatic sites. Thus, even though
multiSNV is superior in correctly detecting the regional dis-
tribution of mutations at somatic sites, Platypus is more ro-
bust to artefactual variation, so a combined approach can
leverage on the strengths of the two algorithms.
To get a high confidence dataset from multiSNV and
Platypus, we retained somatic sites (genomic loci not indi-
vidual calls) that were called by both multiSNV and Platy-
pus, but used multiSNV to call the somatic status over
each sample. The consensus approach helps remove false-
positive sites appearing due tomisalignments and other cor-
related errors, while the more sensitive multiSNV method
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Table 2. Summary of somatic variant calling statistics on the two datasets from (3) using SomaticSniper, MuTect, UnifiedGenotyper, Platypus and multi-
SNV and a combined approach using multiSNV and Platypus together
Method Run time (min) Somatic sites Somatic SNVs %age in dbSNP Validated sensitivity (%) Lowest VAF (%)
SomaticSniper 611 10 922 17 325 8.82 77.8 10.1
SomaticSniper (HC) - 622 1 776 10.3 66.1 12.0
MuTect 13 100 274 792 871 741 32.6 96.5 2.78
MuTect (HC) - 1 410 3 129 16.2 88.3 4.35
UnifiedGenotyper 2 428 6 294 23 638 10.1 90.1 7.69
Platypus 1 169 2 530 10 197 18.5 91.2 5.88
Platypus (HC) - 796 3 968 25.0 90.1 5.88
multiSNV 2 174 21 115 85 809 6.93 97.1 2.78
multiSNV (HC) 429 7 712 20 872 6.15 97.1 2.78
multiSNV (HC) +
Platypus
- 840 3 796 15.0 97.1 2.78
Filters were usedwhenever they were available for the given variant caller to identify a high confidence cohort of calls (denoted byHC). dbSNP concordance
was computed using NCBI dbSNPBuild 137, excluding sites after 129. The last three columns show howwell each variant caller did on the validated SNVs.
Sensitivity was calculated by dividing the total number of true positives by the total number of SNVs that were validated. The last column shows the SNV
with the lowest variant allele frequency that was detected by each variant caller.
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Figure 2. Validated SNVs from exome-sequencing data of patient 1 and patient 2 plotted as a function of the depth of coverage and variant allele frequency.
SomaticSniper has a large number of false negatives even at relatively very high depths of coverage (>150). multiSNV has only five false negatives and of
these four have 0 variant allele frequency in the sequencing reads. Some points on the plots overlie each other.
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identifies the regional distribution of mutations. This ap-
proach generates the top performing caller|-matching the
sensitivity of multiSNV while reducing the original set of
somatic sites by almost 10 times.
DISCUSSION
Several prominent cancer studies have started sequencing
multiple tumour samples from the same patient to dissect
the intratumour heterogeneity of cancer. This creates a need
for a somatic variant caller that extends the Bayesian ap-
proaches used in the analysis of matched tumour-normal
pairs to joint analysis of multiple same-patient samples. The
main challenge is to model the joint distribution of geno-
types (allelic compositions) with no information about the
phylogenetic relationship between the tumour samples. This
is trivial for tumour-normal pairs, as it is reasonable to as-
sume that the (heterogeneous) tumour sample has evolved
from a homogeneous normal sample. In the case of multi-
ple, heterogeneous tumour samples, it is not trivial to infer
the conditional dependencies between the samples. Even in
the case where we have primary and metastatic samples, we
may not assume that amutation present in the primary sam-
ple also exists in the metastatic one, as the given mutation
might have come from a clone present in the primary sam-
ple, and not ancestral to any of the clones in the metastasis.
In this first version of a multisample somatic caller, we
assume samples are independent. More elaborate models
could benefit from an ‘active learning’ approach, so that the
regional distribution of calls is used to learn dependency
structures and update the priors|-this can in turn enhance
the variant calling. Although powerful, such a model runs
the risk of letting false-positive calls update the priors|-this
might falsely bias the variant calling and the inferred depen-
dencies. Independent modelling simplifies statistical mod-
elling and it also allows us to view any inferred dependence
structure as unbiased, as sample dependencies are not used
to call SNVs. It also allows us to make confidence state-
ments about calls, for example when two samples are found
to be empirically similar to one another, we can be more
confident in calls made in one sample, if they are also seen
in the second sample.
Aside being easily generalized to an arbitrary number of
samples, multiSNV also addresses several of the issues that
complicate variant calling from sequencing data. It is more
flexible than some of the current pairwise somatic variant
callers as it is able to identify SNVs at locations that are
germline heterozygous or where no allele matches the ref-
erence. In addition, there is a built-in strand-bias test that
pools reads from all somatic samples to increase the num-
ber of reads before applying Fisher’s exact test. This is a
more powerful approach than testing for strand-bias inde-
pendently and it also has the advantage of generalizing to
multiallelic sites. multiSNV is particularly good at detecting
SNVs at low variant allele frequencies. This is because mul-
tiSNV calls SNVs by identifying the most likely allelic com-
position of each sample based on a likelihood model that
is flexible enough to capture the effects of somatic variation
by allowing for nondiploid genomes and an arbitrarily low
variant allele frequency. As a result, sensitivity to call so-
matic variants depends more on the depth of coverage and
less on the variant allele frequency. Furthermore, whenever
an SNV is shared between multiple samples, multiSNV will
use this information to update the prior probability of ob-
serving an SNV in a particular sample, based on how fre-
quent that SNV is in the other same-patient samples. As
a result, multiSNV has an enhanced ability to resolve low
variant-allele frequencies, particularly in cases where the
SNV is present at higher allele frequencies in other samples.
A downside of this behaviour is that multiSNV will be sus-
ceptible to correlated sequencing artefacts such as context-
related sequencing errors (for example at homopolymers)
or misalignment due to the presence of indels, where ‘false-
positive’ variant reads will be observed across different sam-
ples.
We compared multiSNV against SomaticSniper andMu-
Tect, two widely used pairwise somatic variant callers, as
well as UnifiedGenotyper and Platypus, which are currently
the only available multisample variant callers. We used both
simulated and real datasets. In simulations, most variant
callers showed reasonable robustness to independent se-
quencing noise and multiSNV was one of the better algo-
rithms in this aspect. Moreover, when we assessed algo-
rithms based on their sensitivity to detect mutations present
in multiple tumour samples, we found that the joint anal-
ysis approach in multiSNV consistently outperformed all
other variant callers, particularly the pairwise callers (So-
maticSniper and MuTect), especially when mutations were
present at lower allele frequencies.
We used the multiregion exome sequencing datasets from
(3) to test multiSNV and the four other variant callers us-
ing real data.Where available, we applied tool-specific filters
to reduce the number of calls to a high confidence set. We
found that somatic sites called by multiSNV had the lowest
concordance with dbSNP, both with and without applying
filters. MuTect and Platypus had the highest overlap with
dbSNP, suggesting they might be more prone to miscalling
germline variation as somatic.
multiSNV had the highest sensitivity in correctly identi-
fying the subset of validated SNVs from (3), detecting 97%
of all reported SNVs, in both filtered and unfiltered mode.
It reported only five false negatives, of which four had ob-
served variant allele frequency of 0 in the sequencing data.
TheUnifiedGenotyper identified 90% of all validated SNVs
while calling more SNVs than the high confidence dataset
from multiSNV. After filtering MuTect’s output with the
built-in filters, the number of calls became comparable to
that of SomaticSniper after filtering, but the sensitivity of
MuTect was 27.9% higher. This is an expected result asMu-
Tect is a more recent variant caller that has addressed issues
faced by earlier somatic variant callers. Platypus achieved
a relatively good sensitivity (90.1%) and could detect mu-
tations down to variant allele frequencies of 5.9%, while
being one of the most conservative methods in its overall
number of calls. As the emphasis of multiSNV is calling the
correct regional distribution of mutations rather than de-
tecting misalignments and other artefactual variation, we
show that an optimal approach would be to filter somatic
sites called by multiSNV using Platypus, which specifically
addresses these issues. In future work, we aim to further de-
velop the built-in false-positive filters, but even so, it is likely
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that such integrative approaches will outperform any single
method.
CONCLUSION
Our simulation and whole-exome sequencing analysis re-
sults demonstrate that multisample somatic variant calling
can outperform independent or pairwise independent anal-
yses of multiple related samples. In particular, we show that
multiSNV will identify the correct regional distribution of
mutations down to variant allele frequencies of 2.78%,while
false-positive filtering and consensus approaches can reduce
the overall number of calls with no adverse effect on the
known number of false negatives. We anticipate that mul-
tisample somatic variant calling will become the gold stan-
dard when analysing NGS data from multiregion sequenc-
ing studies with spatially separated samples and longitudi-
nal studies with samples collected at different time-points
to track cancer evolution.
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